ArticleGland surgery2025
Predictive value of the pretreatment serum sialic acid/total protein ratio for bone metastases in newly diagnosed prostate cancer patients: development of a nomogram model.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone is a common site of distant metastasis, and its metastasis is one of the major causes of death in prostate cancer (PCa) patients. Currently, there is a lack of effective predictive methods. This study aimed to evaluate the potential of pretreatment serum sialic acid/total protein (SA/TP) ratio as a biomarker for predicting PCa and its associated bone metastases. Methods: A retrospective analysis was conducted on 641 patients diagnosed with benign prostatic hyperplasia (BPH) or PCa between November 2014 and July 2021. We conducted a comparative analysis of SA/TP levels across various subgroups and investigated the correlation between SA/TP levels and multiple clinical parameters. Independent risk factors were identified through both univariate and multivariate logistic regression analyses, and a predictive model for assessing the risk of bone metastases was developed. Results: PCa patients presented significantly higher median pretreatment SA/TP levels than BPH patients (P<0.001). Furthermore, within the cohort of PCa patients, individuals with bone metastases demonstrated markedly elevated pretreatment SA/TP levels in contrast to their counterparts without bone metastases (P<0.001). Additionally, receiver operating characteristic (ROC) curve analysis identified an optimal cut-off value of 0.7973 for distinguishing BPH from PCa, accompanied by an area under the curve (AUC) of 0.606 [95% confidence interval (CI): 0.559-0.653, P<0.001]. In parallel, the optimal cut-off value for differentiating between bone metastases and without bone metastases in PCa patients was identified as 0.8560 with an AUC of 0.770 (95% CI: 0.707-0.833, P<0.001). Multivariate logistic regression analysis revealed that a pretreatment SA/TP ≥0.7973 was independently correlated with PCa [hazard ratio (HR) =1.704, 95% CI: 1.016-2.806, P=0.04], whereas a pretreatment SA/TP ≥0.8560 served as an independent risk factor for PCa with bone metastases (HR =2.567, 95% CI: 1.051-6.271, P=0.04). Conclusions: The elevated pretreatment SA/TP level is closely associated with the risk of PCa and its subsequent bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.